Shire completes Baxalta takeover

pharmafile | June 3, 2016 | News story | Medical Communications, Research and Development, Sales and Marketing Baxalta, Shire, deal, merger and acquisition, revenue, sales 

UK drugmaker Shire (LSE: SHP) on Friday announced the completion of merger with rare disease specialist Baxalta (NYSE: BXLT). 

The company said it sees the joint firm to deliver double-digit compound annual top-line growth, with over $20 billion in annual projected revenue by 2020 and about 65% of total annual revenues being immediately generated by its rare disease products. 

Following the deal Shire now has more than 50 programs in clinical development, the company said in a statement. 

Shire Chief Executive Officer Flemming Ornskov, said: “Upon the completion of our combination with Baxalta, Shire is now the global leader in rare diseases, with the number one rare diseases platform based on both revenue and pipeline programs.” 

The combined entity will generate annual operating cost synergies of at least $500 million within the first three years post-closing. Further, Shire expects to generate additional revenue synergies and a combined non-GAAP effective tax rate of 16-17% by 2017. 

Anjali Shukla

Related Content


LegoChem and Iksuda expand License Agreement for antibody drug conjugates

Iksuda Therapeutics, a developer of antibody drug conjugates (ADCs), has announced the expansion of the …

Exscientia buys Austrian cancer cell screening company for €50 million

UK-based AI pioneers Exscientia has announced the purchase of rival AI firm Allcyte for €50 …

Novo Holdings acquires BBI Group in £400 million deal

Novo Holdings, a holding company of the Novo Group, has acquired BBI Group from Exponent …

Latest content